Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer

Most of the previous studies of amrubicin in patients with previously treated small-cell lung cancer were conducted at a dose of 40 mg/m(2). The aim of this study was to assess the efficacy and safety of amrubicin at a dose of 45 mg/m(2) in patients with relapsed or refractory small-cell lung cancer...

Ausführliche Beschreibung